SCHEMBL5954570

SCHEMBL5954570

S=C=Nc1ccc(Sc2ccccc2)cc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MIF P14174 2/20 0.64
HSD17B10 Q99714 3/20 0.51
P2RY6 Q15077 2/20 0.47
MAOA P21397 4/20 0.45
MAOB P27338 3/20 0.45
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
HPGD P15428 4/20 0.38
ALDH1A1 P00352 3/20 0.38
ADRA2A P08913 2/20 0.38
ADRA2C P18825 2/20 0.38
ADRA2B P18089 1/20 0.38
KEAP1 Q14145 1/20 0.36
NFE2L2 Q16236 1/20 0.36
CTSK P43235 1/20 0.36
SLC6A4 P31645 2/20 0.35
CYP3A4 P08684 2/20 0.34
ABCB11 O95342 1/20 0.34
NR3C1 P04150 1/20 0.34
CYP1A2 P05177 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL484042 0.91 MIF (0.54) MIFHSD17B10P2RY6MAOAMAOB
SCHEMBL10622884 0.82 MAOA (0.47) MIFHSD17B10P2RY6MAOAMAOB
SCHEMBL331011 0.82 HSD17B10 (0.50) MIFHSD17B10P2RY6CA1CA2
SCHEMBL10622868 0.82 HSD17B10 (0.46) MIFHSD17B10P2RY6CA1CA2
SCHEMBL6211797 0.80 DDAH1 (0.54) MIFHSD17B10P2RY6CA1CA2
Phenylisothiocyanate SCHEMBL20984 0.79
SCHEMBL19713006 0.79 CYP3A4 (0.47) MIFHSD17B10MAOAMAOBHPGD
SCHEMBL11615941 0.79 CYP3A4 (0.47) MIFHSD17B10MAOAMAOBHPGD
SCHEMBL10622883 0.79 MAOB (0.55) MIFHSD17B10P2RY6MAOAMAOB
SCHEMBL483870 0.78 MIF (0.54) MIFHSD17B10P2RY6MAOACA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060025589-A1 2-Thiohydantoine derivative compounds and use thereof for the treatment of diabetes LABORATOIRES FOURNIER S.A. (FR) 2006-02-02 US disclosed
EP-1546111-A2 2-THIOHYDANTOINE DERIVATIVE COMPOUNDS AND USE THEREOF FOR THE TREATMENT OF DIABETES LABORATOIRES FOURNIER S.A. (FR) 2005-06-29 EP disclosed
WO-2004031160-A2 2-THIOHYDANTOINE DERIVATIVE COMPOUNDS AND USE THEREOF FOR THE TREATMENT OF DIABETES LABORATOIRES FOURNIER S.A. (FR) 2004-04-15 WO disclosed
US-4771062-A ENZYME INHIBITORS BAYER AKTIENGESELLSCHAFT (DE) 1988-09-13 US disclosed
EP-0240680-A1 Diaryl sulfide derivatives BAYER AG (DE) 1987-10-14 EP disclosed
US-4112100-A INCREASING THE ENDOGENOUS PRODUCTION OF PROSTAGLANDINS THE UPJOHN COMPANY (US) 1978-09-05 US disclosed
US-3970752-A Coccidiocidal compositions utilizing 1-phenyl-substituted 1,3,5-triazine BAYER AKTIENGESELLSCHAFT (DT) 1976-07-20 US disclosed
US-3948893-A COCCIDIOSIS BAYER AKTIENGESELLSCHAFT (DT) 1976-04-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060025589-A1 2-Thiohydantoine derivative compounds and use thereof for the treatment of diabetes LIPC, CYP4F2, SLC5A2 MIF 3993/4885HSD17B10 44/4885P2RY6 2439/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.